Alkai-Abeyo

Life Biosciences is a clinical-stage biotechnology company pioneering therapies to reverse biological aging and treat age-related diseases. The company was originally structured as a hub-and-spoke model with several specialized subsidiaries, including Alkai (focused on telomerase biology) and Abeyo (focused on epigenetic reprogramming). Today, Life Biosciences has consolidated these efforts to focus on its lead platform of partial epigenetic reprogramming, which utilizes gene therapy to express OSK factors (Oct4, Sox2, and Klf4) to restore youthful gene expression patterns. Their primary clinical focus is on ophthalmic conditions such as glaucoma and NAION, while also developing small molecules for chaperone-mediated autophagy. The company aims to address the underlying causes of aging to improve healthspan and treat chronic conditions associated with senescence.